Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy

Area of Science:

• Biomedical Engineering
• Immunology
• Oncology

Background:

• Cancer nanovaccines aim to boost cytotoxic T cell responses for improved immune checkpoint blockade (ICB) therapy.
• Limited co-stimulatory molecule expression hinders the clinical application of current nanovaccines.

Purpose of the Study:

• To develop a genetically engineered cancer cytomembrane nanovaccine that simultaneously overexpresses CD40L and PD1.
• To enhance antitumor immunity and improve cancer immunotherapy efficacy.

Main Methods:

• Genetically engineered cancer cytomembranes overexpressing CD40L and PD1.
• Utilized tumor antigens and co-stimulatory molecules from cytomembranes for DC activation.
• Assessed nanovaccine lymph node trafficking, retention, and DC maturation.
• Evaluated therapeutic efficacy in a breast tumor mouse model.

Main Results:

• Engineered nanovaccines effectively stimulated dendritic cell (DC)-mediated immune activation.
• PD1 overexpression on nanovaccines blocked the PD1/PD-L1 signaling pathway, enhancing antitumor responses.
• Demonstrated enhanced lymph node trafficking and retention compared to original cytomembranes.
• Achieved twofold increase in DC maturation and significant therapeutic efficacy in a preclinical breast cancer model.

Conclusions:

• Genetically engineered cytomembrane nanovaccines incorporating CD40L and PD1 offer a promising strategy for cancer immunotherapy.
• This approach synergistically enhances antitumor immunity by stimulating T cell responses and overcoming immune suppression.
• The developed nanovaccine presents a simple, safe, and robust platform for advanced cancer treatment.